scyllo-Inositol promotes robust mutant Huntingtin protein degradation.
Abstract
Huntington
disease is characterized by neuronal aggregates and inclusions
containing polyglutamine-expanded huntingtin protein and peptide
fragments (polyQ-Htt). We have used an established cell-based assay
employing a PC12 cell line overexpressing truncated exon 1 of Htt with a
103-residue polyQ expansion that yields polyQ-Htt aggregates to
investigate the fate of polyQ-Htt-drug complexes. scyllo-Inositol is an endogenous inositol
stereoisomer known to inhibit accumulation and toxicity of the
amyloid-β peptide and α-synuclein. In light of these properties, we
investigated the effect of scyllo-inositol on polyQ-Htt accumulation. We show that scyllo-inositol
lowered the number of visible polyQ-Htt aggregates and robustly
decreased polyQ-Htt protein abundance without concomitant cellular
toxicity. We found that scyllo-inositol-induced
polyQ-Htt reduction was by rescue of degradation pathways mediated by
the lysosome and by the proteasome but not autophagosomes. The rescue of
degradation pathways was not a direct result of scyllo-inositol on the lysosome or proteasome but due to scyllo-inositol-induced reduction in mutant polyQ-Htt protein levels.
KEYWORDS:
Autophagy; Huntington Disease; Lysosomes; Neurodegenerative Diseases; Proteasome; huntingtin; scyllo-Inositol- PMID:
- 24352657
- [PubMed - indexed for MEDLINE]
- PMCID:
- PMC3916565
- [Available on 2015/2/7]
Inga kommentarer:
Skicka en kommentar